<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2457">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03074903</url>
  </required_header>
  <id_info>
    <org_study_id>Pro20150001449</org_study_id>
    <nct_id>NCT03074903</nct_id>
  </id_info>
  <brief_title>Does Skyla Insertion Timing Impact Bleeding?</brief_title>
  <official_title>Does Skyla Insertion Timing Impact Bleeding?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rutgers, The State University of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women presenting for contraception will be offered the IUS Skyla and study participation.
      Daily bleeding will be collected for a total of 90 days and correlated with insertion timing
      and baseline endometrial thickness.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2016</start_date>
  <completion_date type="Anticipated">August 1, 2017</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding and spotting as collected by daily texts</measure>
    <time_frame>90 days</time_frame>
    <description>Composite variable of bleeding and spotting for 90 days after Skyla IUS insertion</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Vaginal Bleeding</condition>
  <arm_group>
    <arm_group_label>Early cycle insertion</arm_group_label>
    <description>Participants in this group have the intrauterine system inserted during the first seven days of their menstrual cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late cycle insertion</arm_group_label>
    <description>Participants in this group have the intrauterine system inserted during the remainder of their cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intrauterine system</intervention_name>
    <description>Women having the Skyla intrauterine system at different times during their menstrual cycle report their bleeding patterns through daily texts.</description>
    <arm_group_label>Early cycle insertion</arm_group_label>
    <arm_group_label>Late cycle insertion</arm_group_label>
    <other_name>Intrauterine device</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women presenting for intrauterine device insertion.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged 18-45

          -  Parous or nulliparous

          -  Desire Skyla for contraception

          -  Regular menstrual cycles (21-35 days)

          -  Working mobile phone and willing to accept text messages and report daily bleeding
             data for 90 days

        Exclusion Criteria:

          -  Vaginal or cesarean delivery in the past 12 weeks

          -  Abortion in the past 6 weeks

          -  Uterine anomaly distorting the uterus

          -  Acute pelvic inflammatory disease

          -  Uterine bleeding of unknown etiology

          -  Acute liver disease or tumor

          -  History of progestin-sensitive cancer

          -  Abnormal pap smear awaiting diagnostic or therapeutic intervention
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noa'a Shimoni, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers New Jersey Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tasmiah Choudhury, MPH</last_name>
    <phone>973 972 9065</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Planned Parenthood</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tasmiah Choudhury, MPH</last_name>
      <phone>973-972-9065</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>NJFPC</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tasmiah Choudhury, MPH</last_name>
      <phone>973-972-9065</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SHS</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tasmiah Choudhury, MPH</last_name>
      <phone>973-972-9065</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>March 3, 2017</lastchanged_date>
  <firstreceived_date>February 6, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intrauterine device</keyword>
  <keyword>bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Uterine Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
